REVIEW

Bacterial flagellin—a potent immunomodulatory agent

Irshad A Hajam1, Pervaiz A Dar2, Imam Shahnawaz2, Juan Carlos Jaume2 and John Hwa Lee1

Flagellin is a subunit protein of the flagellum, a whip-like appendage that enables bacterial motility. Traditionally, flagellin was viewed as a virulence factor that contributes to the adhesion and invasion of host cells, but now it has emerged as a potent immune activator, shaping both the innate and adaptive arms of immunity during microbial infections. In this review, we summarize our understanding of bacterial flagellin and host immune system interactions and the role flagellin as an adjuvant, anti-tumor and radioprotective agent, and we address important areas of future research interests.

Experimental & Molecular Medicine (2017) 49, e373; doi:10.1038/emm.2017.172; published online 1 September 2017

INTRODUCTION

The immune system has evolved to fight off microbial invasion through the coordinated action of the innate and adaptive arms of the immunity. Innate immune cells respond to a variety of stimuli, including bacterial, viral, parasitic or fungal infections, via members of structurally related receptors termed toll-like receptors (TLRs). TLRs are evolutionarily conserved type I transmembrane receptors that provide a critical link between innate and adaptive immunity. TLRs do not possess fine specificity, such as that of BCRs, TCRs or adaptive immune receptors, but they can individually respond to a limited but specific number of microbial pathogen-associated molecular patterns (PAMPs). The interaction of PAMPs with the TLRs on innate immune cells regulates the induction of more efficient adaptive immune responses.1 TLRs mostly function as homologous or heterologous dimers, acquiring the shape of a horseshoe, which helps in the direct recognition of PAMPs.2,3 TLRs sense bacterial cell wall components, such as lipopolysaccharide (LPS) (TLR-2/4), lipoteichoic acids (TLR-2/4), CpG DNA (TLR9), flagellin (TLR5) and others (reviewed in refs 4–6). This sensing initiates an intracellular signaling cascade that culminates in the activation of a variety of proinflammatory and immune response genes.1,6 Proinflammatory cytokines provide augmentary signals through the upregulation of co-stimulatory and adhesion molecules, which are essential for the activation of adaptive immune cells and the subsequent development of protective immune responses against the infectious nonself antigens.7,8 In recent years, a number of microbial components have been used as adjuvants to augment the immune responses of poorly immunogenic vaccines. Even though all the adjuvants studied so far have proven to be effective, flagellin, a TLR5 agonist, has been shown more promising results without any major side effects.

Flagellin is the structural component of the flagellum, a locomotory organ that is mostly associated with Gram-negative bacteria. It is characterized by highly conserved N- and C-terminal domains (D1 and D2 domains) with an intervening hypervariable region (D3).9 Earlier, flagellin was viewed as a virulence factor in the context of motility rather than having a role in immune stimulation. The first report of the proinflammatory role of flagellin came from the in vitro studies of Ciacci-Woolwine et al.10 and Wyant et al.,11 and their studies demonstrated that Salmonella flagellin is a potent inducer of cytokines in a pro-monocytic cell line at sub-nanomolar concentrations. Later, McDermott et al.12 reported that induction of the proinflammatory response in monocytes involves a high-affinity interaction between flagellin and the surface receptor present on innate immune cells. This surface receptor, which is responsible for the inflammatory and innate immune activity of flagellin, was demonstrated to be TLR5 by Hayashi et al.,13 and it was subsequently confirmed by many other researchers. Further studies showed that recombinant proteins lacking the hypervariable region did not present the compromised adjuvant activity of flagellin; thus, these results indicate that the D1 and D2 domains are essential for the recognition of TLR5 and are sufficient to induce a proinflammatory response.14,15 The adjuvant potential of flagellin was first reported by Arnon and co-workers,16–18 and it was accordingly tested for adjuvant activity in combination with a number of bacterial, viral or parasitic antigens over the past...
| Antigen/disease agent                                                                 | Model/route                              | Immune response                                                                                                                                                                                                 | References |
|--------------------------------------------------------------------------------------|------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| **Bacterial pathogens**                                                              |                                          |                                                                                                                                                                                                                                                                         |            |
| *Salmonella dublin* flagellin- Schistosoma mansoni 9B-surface antigen                | Mice/i.n.                                | Humoral response, significant protection against *in vivo* challenge                                                                                                                                                                                                   | 138        |
| Maltose-binding protein (MBP) of *C. jejuni*-flagellin                               | Mice/i.n.                                | Systemic and mucosal Ab production, protection against heterologous challenge                                                                                                                                                                                          | 139        |
| *E. coli* heat stable enterotoxin-flagellin                                          | Mice/oral                                | Ab production                                                                                                                                                                                                                                                          | 73         |
| *Y. pestis* F1 antigen+flagellin or flagellin+*Y. pestis* F1-V fusion protein       | Mice, non-human primate/i.n., i.m., intratracheally | Robust antigen-specific IgG Ab response, Th2 type immune response, protection against *in vivo* virulent *Y. pestis* challenge                                                                                                                                           | 45         |
| Flagellin+tetanus toxoid                                                             | Mice/i.n.                                | Systemic and mucosal Ab production (IgG and IgA), protection against lethal dose of tetanus toxin                                                                                                                                                                         | 75         |
| Flagellin-p27 antigen of *Mycobacterium tuberculosis*                                 | Mice/i.m.                                | Ab production, Th1 immune response                                                                                                                                                                                                                                    | 140        |
| *Pseudomonas aeruginosa* OppF epitope 8-OprF-flagellin fusion proteins               | Mice/i.m.                                | Humoral response, protection against challenge                                                                                                                                                                                                                          | 141        |
| Recombinant Pneumococcal surface protein A (PspA)-flagellin (FlaB–PspA)             | Mice/i.n.                                | Systemic IgG and mucosal IgA response, protection against lethal challenge, enhances cross-protective immunity against *Streptococcus pneumoniae* infection                                                                 | 77         |
| Recombinant *FimH*-flagellin                                                        | Mice/s.c.                                | Ab production, Th2-biased immune response, significant reduction in colonization of bladder by uropathogenic *Escherichia coli* (UPEC)                                                                                                                                     | 142        |
| DNA encoded flagellin+Ag85B of *M. tuberculosis*                                     | Mice/i.m.                                | Enhanced T-cell responses to Ag85B, significant protection against pathogenic aerosolized *M. tuberculosis* challenge, boosting through intranasal route resulted in pulmonary inflammation and transient weight loss | 143        |
| Flagellin-Lumazine synthetase (BSL)                                                  | Mice/i.p.                                | Efficient anti-BSL humoral immune responses                                                                                                                                                                                                                           | 144        |
| **Viral diseases**                                                                   |                                          |                                                                                                                                                                                                                                                                         |            |
| Flagellin-Influenza epitopes                                                        | Human-mice radiation chimera/i.n.        | Ab production, protection against lethal challenge                                                                                                                                                                                                                     | 16         |
| Flagellin (STF2D)-EIII domain of WNV envelope protein                               | Mice/s.c., i.p.                          | IgG response, protection against lethal challenge                                                                                                                                                                                                                      | 72         |
| Flagellin-Influenza Virus-Like Particles                                              | Mice/i.m.                                | Th1 immune response, protection against both homologous and heterologous viral challenge                                                                                                                                                                               | 131        |
| Vaccinia virus-flagellin fusion proteins; L1R-flagellin and BSR-flagellin           | Mice/i.m.                                | Humoral response and protection against challenge                                                                                                                                                                                                                      | 145        |
| Flagellin+whole inactivated A/PR/8/34 (PR8) virus                                    | Mice/i.n.                                | Ab protection (IgG2a, IgG2b, IgA), protection against homologous lethal challenge                                                                                                                                                                                           | 43         |
| Flagellin-VLPs of HIV                                                                | Guinea pig/i.m., i.n.                    | Enhanced systemic and mucosal immune response, increased neutralized antibodies                                                                                                                                                                                        | 146        |
| Inactivated FMDV antigen+flagellin                                                    | Guinea pig/i.d.                          | Protected the animals against homotypic viral challenge, Th1-biased immune response                                                                                                                                                                                    | 42         |
| Flagellin-VLPs of rabies                                                             | Mice, dog/i.m.                           | Faster and enhanced virus-neutralizing Ab induction, increased CD4+ and CD8+ T-cell responses, production of strong IgG2a-specific response, protection against virus challenge                                                                                      | 147        |
| **Parasitic pathogens**                                                              |                                          |                                                                                                                                                                                                                                                                         |            |
| *Plasmodium vivax* Merozoite Surface Protein-1 (MSP1) either admixed or fused to flagellin | Mice/s.c., i.n.                        | Elicited strong and long-lasting MSP-1-specific systemic Ab responses                                                                                                                                                                                                  | 148        |
two decades (Table 1). The incorporation of flagellin as an adjuvant has produced safe, potent vaccines, and some of the vaccines eventually made their way into human clinical trials. More significantly, flagellin has also been examined for anti-tumor and radioprotective activities and has shown tremendous potential in combating tumor growth and radiation-associated tissue damage; some flagellin-based anti-tumor vaccines have successfully entered into human clinical trials (Table 2).

**FLAGELLIN SENSING BY IMMUNE AND NON-IMMUNE CELLS**

Flagellin activates immune and non-immune cells via the germ line-encoded pattern recognition receptor TLR5. TLR5 is present on a variety of cells, including monocytes, macrophages, neutrophils, lymphocytes, NK cells, dendritic cells (DCs), epithelial cells and lymph node (LN) stromal cells. It is highly expressed in gut, especially in lamina propria DCs, where it controls the composition of the microflora. The interaction of flagellin with TLR5 results in the induction of a variety of gene expression, including proinflammatory cytokines, nitric oxide (NO), H2O2, chemokines and host-defense proteins. Flagellin activates TLR5-expressing cells either through MyD88-dependent or -independent pathways. MyD88-dependent stimulation recruits downstream adapter molecules that activate the MAP and IκB kinase pathways, leading to the induction of transcription factors AP-1 and NF-κB, respectively, which subsequently activates a variety of genes that are important for host-defense (Figure 1). The MyD88-independent pathway involves the formation of a TLR5/TLR4 heterodimeric complex that activates cells through the TRIF-mediated pathway instead of the MyD88 adapter molecule. TRIF activation induces the production of antiviral cytokine IFN-β via the IRF3 transcription factor. Subsequently, IFN-β results in the activation of the STAT1 transcription factor, which promotes inducible NO synthase (iNOS) gene transcription and NO production (Figure 1).

Certain Gram-negative bacteria, such as *Salmonella*, translocate flagellin into the host cell cytoplasm via a type III secretory system. Type III secretory system is a very common virulence factor utilized by Gram-negative bacteria to facilitate the translocation of effector proteins, such as flagellin, into the cytoplasm of host cells to exert control over distinct host cell functions.
The delivery of flagellin in the host cell cytoplasm is first recognized by the NAIP (NLR family, apoptosis inhibitory protein) family proteins NAIP5 and NAIP6. Subsequently, the flagellin-bound NAIP5/6 complexes interact with NOD-like receptor NLRC4, resulting in the activation of caspase-1, which cleaves pro-interleukin-1 β into active IL-1 β, a potent proinflammatory cytokine that is crucial for host-defense responses to infection and injury. While the conserved N- and C-terminal domains of flagellin are required for TLR-binding activity, the recognition of flagellin by NLRC4 seems to involve the C-terminal amino acids of flagellin, as mutations of specific leucine residues in the C-terminal domain abrogate NAIP5/NLRC4-mediated inflammasome formation.

Flagellin is also recognized by plant cells via flagellin sensing 2 (FLS2), which is a leucine-rich repeats receptor kinase and a homolog of TLR5. FLS2 interacts only with the linear motif in the N-terminal of flagellin, whereas TLR5 interacts with both the N- and C-terminal domains. The recognition of flagellin by FLS2 results in the rapid phosphorylation of MAP kinase pathway, which subsequently culminates in the production of host-defense proteins that mediate protection against fungal and bacterial infections. Flagellin is also recognized by the FLS3 receptor in certain solanaceous plants, including tomato, potato and pepper. FLS3 recognizes flgII-28, a region of bacterial flagellin that is distinct from the region perceived by the FLS2 receptor, and enhances immune responses that protect leaf tissues against bacterial colonization.

Table 2 Flagellin as an anti-tumor agent

| Treatment | Model/route | Effect | References |
|-----------|-------------|--------|------------|
| Flagellin+D2F2 tumor cells | Mice/s.c. | Increased IFN-γ/IL-4 ratio, decreased frequency of Treg cells, significant reduction of tumor growth, CD8+ cytotoxic immune response | 103 |
| Flagellin+CpG motifs | Mice/s.c. | Promoted Th1 polarization, synergism between TLR5 and TLR9, complete remission of tumor growth | 103 |
| Flagellin treatment | Mice/i.p. | Protection against radiation, induction of radioprotective genes | 27 |
| TLR5 activation on breast cancer cells | Mice/i.v., mammary fat pads | Neutrophil infiltration in vivo, increased autophagy protein MAP1S in cancer cells, autophagy of cancer cells, inhibited tumor growth in vivo | 155,156 |
| Salmonella enteritidis serovar Typhimurium infection | In vitro | Apoptosis of adenocarcinomic human alveolar basal epithelial cells A549 in vitro | 157 |
| Flagella-based MUC1 vaccines | Balb/c, or human MUC1 transgenic mice | Flagellin increased higher efficiency of therapeutic activity of MUC1-based vaccines, significant reduction in size and growth rate of the tumor, lowered number of metastases, expanded life span of vaccinated mice | 158 |
| Flagellin+glucose-regulated protein 170 (Grp170) | Mice | Protection against melanoma, colon and prostate cancer, induction of potent CD8+ T-cell responses | 109 |
| Flagellin+E6/E7 peptide of papillomavirus | Mice/s.c. | Elicitation of tumor-specific IFN-γ producing CD8+T cells, retarded in vivo tumor growth, prolonged survival | 117 |
| Flagellin-derived TLR5 agonist, CBLB502 | Mice/i.v. | Protected mice from tumor death, increased NK cell and CD8+ cytotoxic activities, clinical trial in patients with advanced solid tumors is currently ongoing | 111 |
| Flagellin+P10 peptide of Paracoccidioides brasiliensis | Mice/i.n. | Activation of tumor-specific CD4+ T lymphocytes, marked reduction of lung nodules, significant increase in survival, protection against metastatic melanoma growth after adoptive transfer | 159 |

Abbreviations: i.n., intranasal; i.p., intraperitoneal; i.v., intravenous; s.c., subcutaneous.
interaction with TLR5. A study by Hatai et al.\textsuperscript{[40]} shows that TLR5 strongly interacts with flagellin at both acidic and neutral pH conditions, whereas acidic conditions are essential for TLR11–flagellin interactions. Furthermore, this study shows that both the N- and C-terminal domains of flagellin can independently interact with TLR11, whereas the TLR5–flagellin interaction requires both domains to mediate a proinflammatory cytokine response and thus adjuvant activity.\textsuperscript{[14]} TLR11 is highly expressed in epithelial cells in various organs, such as intestine, lung and skin, and it has a role in the prevention of \textit{Salmonella} invasion in mice.\textsuperscript{[41]} This result is in contrast to TLR5-deficient mice, which show enhanced resistance against oral \textit{Salmonella} infection.\textsuperscript{[56]} These findings clearly suggest that flagellin–TLR11 signaling mechanisms differ from flagellin–TLR5 interactions, and therefore, active research is needed in this regard.

**HOW DOES FLAGELLIN CONTRIBUTE TO THE ADJUVANCITY OF VACCINES?**

Flagellin has shown tremendous potency as an adjuvant, either in the context of a fusion protein or by co-administration with antigens.\textsuperscript{[19,20,42,43]} The presence of TLR5 on a number of innate and adaptive immune cells might form the basis of its adjuvant activity (Figure 3). Most of the adjuvants, including TLR agonists, mediate their activity, in part, by activating the innate immune system, including DC activation, maturation and recruitment to T-cell areas in the LNs.\textsuperscript{[44]} Flagellin is a potent activator of both the innate and adaptive immune system. Studies have demonstrated that the dose of flagellin required to promote a maximal antigen-specific antibody response is relatively less than the dose required to stimulate maximal innate immune responses,\textsuperscript{[29,45]} suggesting that the induction of an antibody response is not linearly dependent on the strength of an innate immune response. This result is most likely due to the ability of flagellin to stimulate the induction of proinflammatory cytokines and chemokines in a number of innate and non-immune cells, including DCs, NK cells, epithelial cells and LN stromal cells.\textsuperscript{[24,25,46,47]} which is critical for the activation and development of antigen-specific adaptive immune responses. The administration of flagellin or flagellin-based vaccines has also been shown to rapidly achieve a higher concentration in draining LNs, which therefore activates DCs and non-immune cells, such as epithelial and LN stromal cells.\textsuperscript{[47,48]} The activation of these cell types by flagellin or flagellin-based vaccines leads to the induction of cytokines and chemokines, which promote a marked recruitment in T and B lymphocytes to draining LNs,\textsuperscript{[29,49]} and thus maximizes the chances of antigen-specific lymphocytes encountering their cognate antigens. These mechanisms reasonably contribute to the overall potency of flagellin-based vaccines.

The interaction of flagellin with DCs is either direct or indirect, depending on the type of DC involved; for instance, myeloid-derived DCs respond directly to flagellin through TLR5, while splenic DCs respond indirectly to flagellin and are most likely activated through a bystander process that requires the stimulation of other TLR5-expressing cells.\textsuperscript{[50–52]} There are also indications that the effect of flagellin is dependent on the immunological site involved as, unlike splenic DCs, DCs in lamina propria respond directly to flagellin.\textsuperscript{[53]} There are many discrepancies in the literature regarding the interaction of flagellin and DCs in different species. Some investigators showed the stimulatory effect of flagellin on murine bone marrow-derived DCs,\textsuperscript{[24,25,54,55]} while others reported an effect on human myeloid-derived DCs, but not murine DCs.\textsuperscript{[56]} This variation in responses might be due to a number of factors (reviewed in ref. 47). The quality of flagellin also influences the outcome of experimental results. Recombinant flagellin, if used as an adjuvant, should be free of any endotoxins or nucleic acids as they activate the DCs in a TLR5-independent manner. In addition, long-term storage of some fusion proteins causes molecular aggregation, which activates cells in a TLR5-independent manner, as has been reported with the polymeric flagellin that directly stimulates B cells.\textsuperscript{[57]} The ability of cells to respond to flagellin also depends on the state of differentiation. The pretreatment of innate immune cells with GM-CSF and IL-4 makes them more responsive to flagellin compared to untreated cells.\textsuperscript{[10,47]} Flagellin of different bacterial species also varies in immunogenicity,\textsuperscript{[43]} and not all bacterial flagellins activate TLR5.\textsuperscript{[58]} In contrast to the flagellins of \(\gamma\)-proteobacteria, flagellins from the \(\varepsilon\)-proteobacteria \textit{Campylobacter jejuni} and \textit{Helicobacter pylori} do not activate TLR5 signaling and thus can evade TLR5-mediated immune surveillance at mucosal surfaces.\textsuperscript{[58]} This difference, in part, might be attributed to the structural differences among the flagell of different microbes; for instance, flagellin of \textit{C. jejuni} consists of 7 protein-filaments instead of the 11 found in the \(\gamma\)-proteobacteria \textit{Salmonella}, which contains highly conserved residues between the protofilaments that are involved in the TLR5 interaction.\textsuperscript{[59,60]} The functional differences between TLR5-activating flagellins and non-activators might also be attributed to sequence variations among the flagellins of bacteria species. For instance, the hot spot residues (residues 89 and 114) on the flagellins of \(\gamma\)-proteobacteria that make complementary contacts with TLR5 are replaced with threonine and aspartate residues, respectively, in \textit{C. jejuni} and \textit{H. pylori} flagellins. Thus, \textit{C. jejuni} and \textit{H. pylori} flagellins might fail to make complementary contacts with TLR5 and subsequently fail at TLR5 activation.\textsuperscript{[61]}

Another factor that contributes to the adjuvant activity of flagellin is the presence of TLR5 on the cells of the adaptive immune system, T and B cells. Flagellin directly influences the phenotype and functions of these cells, and thereby directly regulates the adaptive immune system. Most of the studies in humans have shown that flagellin directly activates T cells and is equivalent to anti-CD28 in stimulating the proliferation of T cells.\textsuperscript{[52,63]} A study by Means \textit{et al.}\textsuperscript{[56]} shows that flagellin-treated DCs have a slightly lower stimulatory T-cell effect than LPS-treated DCs, and flagellin stimulation induces the expression of chemokines GRO-\(\alpha\), GRO-\(\beta\), GRO-\(\gamma\), IL-8, MCP-1, MIP-1\(\alpha\), MIP-1\(\beta\) and RANTES in DCs. The induction of these chemokines is very rapid and occurs even before the expression of homing chemokine receptors, thereby recruiting

Experimental & Molecular Medicine

**Immunomodulatory potential of flagellin**

IA Hajam \textit{et al.}
lymphocytes to the secondary lymphoid sites. This outcome indicates that flagellin not only stimulates adaptive immune responses, but also recruits innate immune cells to the sites of infection or immunization. Thus, flagellin activates T cells in two ways: one is direct activation of T cells and the other is via presentation of the cognate antigen by antigen-presenting cells.

Flagellin also activates T regulatory cells (Tregs), which are potent suppressors of T-cell responses and possess higher levels of TLR5 than CD4+ CD25- T cells. However, flagellin may simultaneously inhibit TCR-mediated Treg activation via a suppressor of the cytokine signaling 1-dependent mechanism, albeit these studies are currently lacking in the literature. Thus, the contribution of flagellin-mediated Treg activation and suppressor of the cytokine signaling 1-dependent regulation in the overall adjuvant potential of flagellin-based vaccines warrants further studies.

B cells are directly activated by flagellin through either cross linking of BCRs or signaling through TLR5, depending on the form of flagellin that is involved. B cells require TLR5 signaling, in addition to T-cell help, for T-dependent antibody production or production can occur in presence of cytokines, such as TNF-α. Monomeric flagellin activates TLR5 signaling in B cells and promotes a long-lasting, T-dependent antibody response. In contrast, polymeric flagellin directly stimulates B cells by cross linking BCRs and generates antibody responses of the IgM type without the help of T cells.
adjuvant. The elicitation of immune responses at mucosal surfaces through the use of flagellin has the potential to eradicate or at least prevent the bad outcome of diseases. During the past two decades, flagellin has been extensively tested as a mucosal adjuvant against epitope-based influenza vaccines, West Nile virus (WNV), Yersinia pestis, Clostridium tetani, C. jejuni, Streptococcus and Plasmodium falciparum.

The induction of cytokines and chemokines is key to the adjuvant potential of flagellin. Flagellin is a more potent activator of epithelial cells than LPS and polarizes the response toward IL-8 secretion at epithelial surfaces. Eaves-Pyles et al. showed that flagellin causes rapid degradation of IκB, the inhibitor of NF-κB, in epithelial cells, and induces a variety of pro-inflammatory mediators, including NO, IL-6, IL-8, CXCL2 and cytotoxic genes. These mediators play an important role in the activation of innate and adaptive immune responses at mucosal surfaces, thus mediating protection against the intruding pathogens. NO enhances IgA class switching and production by upregulating TGFβRII expression on B cells and by inducing the expression of BAFF and APRIL in DCs. Moreover, NO and CXCL2 play an important role in the activation and recruitment of professional antigen-presenting cells at a mucosal site, where they pick up and transport the foreign antigens to the draining LN for presentation of the processed antigens to the CD4+ T cells, which is essential for the development of effective antigen-specific immune responses. Furthermore, these mediators recruit neutrophils and professional killer cells at mucosal surfaces, thus providing nonspecific protection against the intruders.

The cytokine IL-6 helps in the development of effective and potent mucosal immune responses and protects the host against bacterial and viral infections. Flagellin is the major determinant in Crohn’s disease, a chronic intestinal disorder caused by inappropriate immune responses to commensal intestinal microflora generated by the interaction of TLR5 present on the epithelial cells and flagella in the intestinal milieu. This implies that flagellin is a potent inducer of pro-inflammatory cytokines at mucosal surfaces and that it is sufficient to overcome oral tolerance, which is a major pitfall for the mucosal route delivery of vaccines. Flagellin-adjuvanted vaccines administered through a mucosal route have been shown to elicit a strong antibody and cell-mediated immune responses, both at mucosal surfaces and at systemic level.

Plant-expressed flagellin has proven potent adjuvant activity for orally administered antigens. A study by Girad et al. showed that orally administered, lyophilized plant powder containing plant-expressed flagellin and ovalbumin induced ovalbumin-specific humoral and cell-mediated immune responses and thus prevented the occurrence of oral tolerance. All these findings clearly indicate that flagellin has a substantial potential to act as a mucosal adjuvant. In addition to its role in mucosal adjuvanticity, TLR5 also plays a role in controlling bacterial infections at mucosal surfaces.

Furthermore, flagellin also promotes class switching in B cells, thus generating more potent and diverse antibody responses. In addition to TLR5, the recognition of flagellin by inflammasomes (NLRC4) also plays an important role in the generation of antibody responses, and either TLR5 or inflammasome (NLRC4) is necessary and sufficient for the production of humoral immunity. However, López-Yglesias et al. reported that anti-flagellin IgG1 antibody responses develop through TLR5- and inflammasome-independent pathways, suggesting that other receptors or distinctive pathways are involved in the generation of humoral responses. The elucidation of other pathways of recognition will clearly contribute to a better understanding of flagellin-host interactions and will be critical for the rational design of flagellin-based vaccines.

**FLAGELLIN AS A MUCOSAL ADJUVANT**

The administration of vaccines through the mucosal route is an attractive idea, albeit the adjuvants that elicit robust immune responses at mucosal surfaces are lacking. The presence of TLR5 on epithelial cells, which are often the first major cell types to encounter infectious and non-infectious agents, might form the basis for prospects of flagellin as a mucosal adjuvant.
that a common stop codon polymorphism in TLR5 in lung epithelial cells abolishes flagellin activity and increases the incidence of human lung infections by flagellated bacteria. This case signifies that TLR5 have an innate immune regulatory role in lung epithelial cells as well.

**FLAGELLIN AS AN ANTI-TUMOR AGENT**

TLR agonists have also been tested for anti-tumor activity in animal models and some of them have eventually made their way into human clinical trials (reviewed in refs 95–97). The immunobiology of TLRs in tumor progression or regression is very intricate and complex. Some studies show that activation of TLR4 or TLR9 on cancer cells promotes tumor progression and growth, whereas others show that TLR3 and TLR5 activation exhibits inhibitory effects. Among TLR agonists, the effect of flagellin is unique, as it does not involve the innate arm of immunity in combating tumor growth but rather is entirely dependent on the activation of adaptive immunity. Sfondrini et al. reported that administration of purified flagellin at the time of tumor transplantation enhanced tumor growth, whereas the same flagellin resulted in the regression of a palpable tumor. This finding can be explained by way of the immune bias induced by flagellin in response to weak or highly immunogenic tumors. The interaction of flagellin with highly immunogenic tumors induces a Th1 response and suppression of Tregs, resulting in the inhibition of tumor growth. However, weakly immunogenic tumors polarize the response toward Th2, which prevents the apoptosis of Tregs and increases their suppressive effect on CD4+ Th1 cells, favoring tumor growth. This result also suggests that preactivated adaptive immunity is critical to the anti-tumor activity of flagellin. The combination of flagellin with CpG-ODN has been shown to abrogate the negative effect of flagellin on tumor growth and has produced a synergistic response in tumor inhibition. This might be due to induction of IL-12 and IL-23 expression in DCs and consequent Th1 bias, as has been reported with the combination of flagellin and other TLR agonists. Recently, Salmonella typhimurium has been used to express and secrete flagellin of *Vibrio vulnificus* as an anti-cancer agent against a variety of cancers in mouse models. This study shows that flagellin-secreting Salmonella targeted to the tumor microenvironment exerted potent tumoricidal activity through two-step activation of the TLR4 and TLR5 signaling pathways. The tumor suppressive effects of flagellin-secreting Salmonella were far more potent than those mediated by Salmonella harboring an empty vector, indicating synergistic effects of the TLR4 and TLR5 signaling pathways in combating tumor growth. In addition to the crosstalk between TLRs, Nod-like receptors (NLRs) inhibit tumor progression and act in concert with TLR5 to induce potent anti-tumor activity. A study by Garraud and Blander shows that engineered flagellin-bearing tumor...
cells elicit robust anti-tumor T-cell responses and tumor rejection in mice. This anti-tumor activity, mediated by flagellin, is dependent on the activation of both TLR5 and NAIP5, as abrogation of either NLR or TLR5 signaling restored the ability of flagellin-bearing tumor cells to form tumors in vivo and impaired immune responses, respectively. This explains why some TLR ligands tested as single adjuvants in phase II and III clinical trials failed at providing significant tumor regression.\(^\text{107}\) The crosstalk of TLR5 and NOD1 is supported by another study, which shows that combined stimulation of both the receptors strongly potentiates NF-κB activity, resulting in the elicitation of potent innate immune responses and protection against Salmonella infection.\(^\text{108}\) These findings clearly indicate the great potential for dual targeting of TLRs and NLRs in the design of optimal cancer vaccines.

Cancer immunotherapy aims to mount effective anti-tumor T-cell responses to control tumor growth and metastasis. Although this approach holds great promise for cancer treatment, its therapeutic application in chemotherapy has been limited so far. Despite the innate ability of the immune system to recognize tumor cells, several potential mechanisms are exploited by cancer cells to create an immunosuppressive environment that enables them to escape immune destruction. Thus, novel strategies should be employed to overcome immunosuppressive mechanisms and the induction of effective anti-tumor immunity. A study by Yu et al.\(^\text{109}\) shows that adenovirus expressing a fusion protein of flagellin and Grp170, the largest endoplasmic reticulum chaperone, induces a potent anti-tumor response against B16 melanoma and its distant lung metastasis compared to the co-administration of Grp170 and flagellin. The therapeutic potential of this treatment was also confirmed in mouse prostate cancer and colon carcinoma.\(^\text{109}\) The flagellin-Grp170 fusion resulted in the superior presentation of tumor antigens by DCs to CD8\(^+\) T cells, which subsequently elicited potent cytotoxic CD8\(^+\) T-cell responses, both locally (that is, tumor site) and systemically.\(^\text{109}\) The tumor microenvironment can also be ameliorated to elicit anti-tumor responses through TLR5 ligand-secreting T cells, as reported by Kaczanowska and Davila.\(^\text{110}\) These studies suggest that targeting the tumor microenvironment with such novel strategies has great potential to overcome the immunosuppressive mechanisms of tumors and to induce effective anti-tumor immunity. Flagellin exclusively acts as a potent T-cell adjuvant to mediate anti-tumor immunity. Leigh et al.\(^\text{111}\) shows that a Salmonella flagellin-derived, pharmacologically optimized TLR5 agonist, CBLB502, stimulates robust anti-tumor activity through the direct activation of TLR5-expressing accessory immune cells, which subsequently stimulate cytotoxic CD8\(^+\) T cells. The anti-tumor potential of CBLB502 is further shown in another report. This report demonstrates that the strongest NF-κB activation in response to CBLB502 occurs in the liver and GI tract, where liver hepatocytes and lamina propria DCs, respectively, are responsible for the primary CBLB502 response.\(^\text{112}\) CBLB205 agonist suppresses the liver metastases of different kinds of cancer regardless of their TLR5 status, indicating the activation of TLR5-bearing cells present in the tumor microenvironment, which in turn execute anti-tumor activity.\(^\text{112}\) To elucidate the exact role of innate immune cells, especially NK and DCs, in mediating the anti-tumor potential of flagellin, Brackett et al.\(^\text{113}\) reported that the TLR5 agonist entolimod (formerly named CBLB502) mediates anti-tumor activity through the NK-dendritic-CD8\(^+\) T-cell axis. Entolimod activates NF-κB-, AP-1- and STAT3-driven immunomodulatory signaling pathways specifically within the liver and rapidly induces chemokines, such as CXCL9 and -10, which recruit blood-borne CXCR3-expressing NK cells to the liver.\(^\text{113}\) NK cell-driven activation of DCs results in the elicitation of potent CD8\(^+\) T-cell responses, which exert both the anti-metastatic effect of entolimod and the induction of tumor-specific memory responses.\(^\text{113}\) These findings clearly indicate the potential of TLR5 agonists as potent organ-specific immunoadjuvants, enabling efficient anti-cancer immunization that does not rely on the recognition of tumor-specific antigens. In contrast to the TLR5-negative environment outside of the liver, the tumor must bear the TLR5 receptor to mediate the anti-tumor activity mediated by flagellin.

The expression of TLR5 has been used as a novel predictive marker for the recurrence and survival of various types of cancers.\(^\text{114}\) The expression of TLR5 has been shown to increase in various types of cancers, such as in gastric and colorectal carcinogenesis. Rhee et al.\(^\text{115}\) reported that gastric carcinoma expresses high levels of TLR5 and that treatment with flagellin elicits a potent anti-tumor activity. Flagellin induces the activation and proliferation of DCs and fibroblasts through the degradation of apoptosis-inducing protein\(^\text{116}\) p27, while the activation of TLR5 on carcinoma cells inhibits proliferation and anchorage-independent growth. The activation of separate signaling pathways by flagellin in different cell types clearly warrants further research. Nguyen et al.\(^\text{117}\) demonstrate that flagellin acts a potent adjuvant for E6/E7 proteins of human papillomavirus and induces a strong CD8\(^+\) T-cell response, which suppresses tumor growth and prolongs survival. This flagellin-based anti-tumor therapeutic vaccine resulted in the complete remission of lung metastasis through the activation of CD8\(^+\) T cells, involving the MyD88-dependent pathway. Thus, flagellin exclusively acts as an adjuvant for T cells and has the potential to be used for anti-cancer immunotherapy, even for TLR5 non-expressing tumor cells.

**FLAGELLIN AS A RADIOPROTECTIVE AGENT**

In addition to being a potent immunomodulatory and anticancer agent, flagellin also possesses a radioprotective property that protects the host against ionizing radiation. Radiation-induced tissue toxicity remains a major challenge in the delivery of tumoricidal doses of intestinal irradiation. Several significant studies have demonstrated the radioprotective potential of flagellin. Vijay-Kumar et al.\(^\text{27}\) reported that systemic administration of flagellin protects mice against irradiation in a TLR5-MyD88 manner. This protection is mediated by the cells of the innate immune system, which release cytoprotective cytokines, such as G-CSF, a known radioprotectant.\(^\text{118}\) The exploitation of flagellin as a
radioprotective agent seems to be dependent on the time of the administration of flagellin and the dose of radiation. The administration of flagellin is beneficial up to 4 h following irradiation, whereas there is no beneficial effect following 24 h post irradiation.\textsuperscript{27} This indicates that the early activation of innate immune cells plays an important role in combating the adverse toxicity of radiations. Other studies have also reported the radioprotective potential of flagellin. Burdelya \textit{et al.}\textsuperscript{119} reported the radioprotective activity of a TLR5 agonist, CBLB502, and demonstrated that a single injection of this drug before lethal total-body irradiation protected mice and rhesus monkeys from both gastrointestinal and hematopoietic acute radiation syndromes and prolonged survival. Improved survival is also observed after irradiation, but at lower radiation doses. This radioprotective property is dependent on the activation of NF-κB signaling pathway, which subsequently culminates in the production of anti-apoptotic proteins, scavengers of ROS and growth factors. These factors play an important role in CBLB205’s protection against gastrointestinal and hematopoietic acute radiation syndromes.\textsuperscript{112,119} CBLB502 also induces additional prosurvival signals via the STAT3 and AP-1 signaling pathways, which are responsible for liver resistance to Fas-mediated apoptosis.\textsuperscript{112} Furthermore, CBLB502-treated mice show higher concentrations of G-CSF and IL-6 in blood, which are known stimulators of hematopoietic stem cells (G-CSF) and the thrombopoietic lineage of hematopoiesis (IL-6).\textsuperscript{112} The radioprotective potential of flagellin is also attributed to its ability to modify the recruitment and phenotype of macrophages. A study by Lacavé-Lapalun \textit{et al.}\textsuperscript{120} shows that the administration of flagellin 3 days after irradiation is associated with the transition of macrophages from a primarily proinflammatory M1 to a more anti-inflammatory M2 phenotype. This transition of phenotype resulted in a notable decrease of the acute damaging effects of radiation by reducing the inflammatory response and enhancing epithelial repair. All these findings clearly suggest that flagellin and a flagellin-derived agonist could potentially improve/expand the therapeutic window of tumoricidal doses of irradiations and thus serve as a biological protectant in radiation emergencies.

**BENEFITS OF FLAGELLIN-BASED VACCINES**

Flagellin-based vaccines have the potential to provide protection against various insults, including radiation, chemicals and pathogens. Previously, LPS has been used as a protective agent against such challenges and as vaccine adjuvant, but only to a limited extent, as it induces sepsis and pulmonary lung inflammation, even at low doses.\textsuperscript{121,122} Furthermore, LPS is a poor activator of epithelial cells,\textsuperscript{123} which are often the first cells to encounter pathogens and chemicals, and hence it may not provide optimum protection. The expression of TLRs varies in various organs and thus its protection varies against various kinds of challenges. A study by Burdelya \textit{et al.}\textsuperscript{112} demonstrates that treatment with a TLR5 agonist, CBLB205, but not with LPS, improves survival of mice infected with a lethal dose of \textit{S. typhimurium}. This study further reports that in response to CBLB502 treatment, liver hepatocytes show the highest NF-κB expression, while LPS-activated NF-κB expression specifically occurs in the lungs, spleen and kidney; thus, these results make biological sense, as the liver is the primary site of \textit{Salmonella} residence during infections. This indicates that the tissue specificity of TLR5 and TLR4 expression plays an important role in providing protection against different kinds of challenges and that LPS and flagellin may act as organ-specific immunomodulators. The use of flagellin over LPS is advantageous. Flagellin and a flagellin-based TLR5 agonist are significantly less toxic than agonists of many other TLRs.\textsuperscript{27,112} Flagellin induces the non-pathologic profile of cytokines and mediates less of the adverse effects associated with LPS.\textsuperscript{112,124} Flagellin is a potent activator of epithelial cells and a generally poor activator of hematopoietic cells, such as macrophages and DCs, which mediate sepsis.\textsuperscript{21} Flagellin-induced TLR5 signaling in epithelial cells results in the upregulation of cytokines, cytoprotective genes and other host–defense genes, which provides nonspecific protection against a variety of challenges, including orally ingested chemicals and pathogens, such as \textit{Salmonella} and rotavirus infections.\textsuperscript{27} There is also a report that flagellin treatment curtails the symptoms of allergy that are usually associated with an allergen.\textsuperscript{125} Flagellin also mediates protection against ionizing radiations, which cause damage to various organs, particularly rapidly dividing mucous membranes. A 2-h prior exposure of flagellin has been found to provide protection against radiation and thus can be used prophylactically at the time of nuclear disaster.\textsuperscript{27} Flagellin has also been shown to induce antibacterial gene expression and heat shock proteins, which equips epithelial cells to better address pathogens and radiation.\textsuperscript{126} A flagellin-based TLR5 agonist, entolimod (CBLB502), has been used to reduce the systemic toxicity of 5-fluorouracil, an anti-tumor chemotherapy, and has improved the integrity of intestinal tissue and has stimulated hematopoiesis following treatment.\textsuperscript{127} This indicates that flagellin or a flagellin-based agonist has the clinical potential to broaden the therapeutic window of genotoxic anti-tumor drugs. Therefore, approaches should include flagellin in therapies or prophylaxis to provide broad-spectrum protection against various kinds of challenges.

One of the major concerns with use of protein-based adjuvants, such as flagellin, is the induction of antibody responses that might neutralize their adjuvant potential and diminish or suppress the immune response against the antigen on subsequent immunizations. Prior immunity to flagellin does not hamper antibody production against the antigen.\textsuperscript{17} Furthermore, Eaves-Pyles \textit{et al.}\textsuperscript{14} reported that conserved regions of flagellin are sufficient to induce a proinflammatory response in immune cells. Thus, the anti-flagellin immune response could be minimized by using the conserved regions only. Moreover, the plasticity of flagellin allows the creation of fusion proteins without compromising the conformational epitopes.\textsuperscript{20} The foreign antigens can be physically linked to the N- or C-terminal or the hypervariable region can be replaced. Song \textit{et al.}\textsuperscript{128} fused the HA globular head of H1N1 influenza virus to the C-terminal of flagellin, which protected
mice against lethal challenge and was immunogenic and well tolerated in humans. In a subsequent study, they replaced the hypervariable region of flagellin with the HA globular head of H5N1 and found that it was more efficacious and immunogenic than the previous design.129 These influenza vaccines have elicited robust, long-lasting (>8 month) neutralizing antibody responses, have protected mice against lethal challenges and are currently under clinical trials.129,130 Immunogenic antigens of other pathogens have also been fused to flagellin; for instance, fusion of the C-terminal end of merozoite surface protein-1 (MSP-19) with the C-terminal end of flagellin developed strong, specific and long-lasting antibody-mediated responses.79 The booster immunization showed that the immune response was similar to emulsified complete or incomplete Freund’s adjuvanted vaccine.79

Flagellin has shown adjuvant potential both as a fusion protein or in its co-administration with an antigen without any physical linking.19,42,43 However, there is a minor discrepancy in the literature regarding the use of flagellin in the context of a fusion partner or in its co-administration with an antigen. Some studies have shown that the co-administration of flagellin with an antigen does not augment the immune response and therefore, physical linking of flagellin with an antigen is required for its adjuvant activity.131 We and others have shown that there is no requirement for the physical linking of flagellin to the antigen and that co-administration generates potent immune responses.42,43,129 All these studies show that flagellin augments immune response manifold and protects animals against a lethal challenge. Linking the antigen to flagellin might be a superior strategy due to the better activation of DC through TLR5 signaling, which provides a means for efficient antigen internalization and access to the antigen processing pathway. In addition, flagellin has the potential to act as an adjuvant of its own against one or more epitopes present in the hypervariable region.133

Most adjuvants are effective in young or middle-aged populations and are less efficient in older people, who are in dire need of good quality adjuvants or vaccines. Flagellin has shown effective adjuvant activity in aged mice and has enhanced antigen-specific systemic and mucosal immune responses, but this response occurred at a less robust level than that in young mice.134,135 Flagellin induced an efficient immune response in elderly subjects immunized with a recombinant hemagglutinin influenza–flagellin fusion vaccine (VAX125).136 In addition, flagellin has been shown to enhance cross-protective responses of related antigens; for instance, intranasal immunization of mice with recombinant PsPA fused to flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection.77 All these findings suggest that the benefits and potential of flagellin are unlimited.

CONCLUSION
Related to the use of flagellin as an adjuvant and anti-tumor agent, there are many areas worthy of continued investigation. What are the long-term consequences of the use of flagellin in the context of dosage and the route of administration? Are other receptors or pathways, besides TLR5 and NLRC4, involved in flagellin perception and/or mediation of immunity in mammals? Do distinctive pathways exist for flagellin in different kinds of cells, for instance, in normal and cancerous cells? To what extent does inflammamome-mediated recognition of flagellin contribute to the overall innate immune response and the adaptive immune response? The answers to these questions should provide a solid basis for the use of flagellin as an effective adjuvant and anti-tumor agent in the future.

In addition, there is accumulating evidence that implicates flagellin for inflammatory diseases, such as acute lung inflammation, cardiovascular collapse, inflammatory bowel disease and lung injury.90,137 These effects from the use of flagellin could be minimized or avoided by using very small doses of flagellin or flagellin-based fusion proteins. For instance, ‘Vax-Innate’s Universal Flu Vaccine’ has shown in phase 1 clinical study that 0.3 and 1.0 μg doses are safe and immunogenic, while 3 and 10 μg doses were associated with flu-like symptoms. A study by Treanor et al.136 in humans has also demonstrated that doses above 3 μg have produced moderately severe systemic symptoms accompanied by substantial increases in serum C-reactive protein. Another alternative to minimize toxicity concerns might be the use of a combination of flagellin with another TLR agonist, such as TLR3 or TLR9 ligand, or the use of flagellin in combination with NLRs. These strategies will result in more pronounced effects than individual agonists, especially against tumors36,103 and will help reduce the dose of the agonists and toxicity.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

ACKNOWLEDGEMENTS
This work was supported by the National Research Foundation of Korea (NRF) in a grant funded by the Korean government (MISP) (No. 2015R1A2A1A14001011).

PUBLISHER’S NOTE
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

1 Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2001; 2: 947–950.
2 Liew FY, Xu D, Brint EK, O’Neill LAJ. Negative regulation of Toll-like receptor-mediated immune responses. Nat Rev Immunol 2005; 5: 446–458.
3 Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124: 783–801.
4 Medzhitov R, Janeway C. Innate immune recognition: mechanisms and pathways. Immuno Rev 2000; 173: 89–97.
5 Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011; 34: 637–650.
6 Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 2003; 85: 85–95.
7 Granucci F, Feau S, Zanoni I, Pavelka N, Vizzardelli C, Raimondi G et al. The immune response is initiated by dendritic cells via interaction with...
microorganisms and interleukin-2 production. J Infect Dis 2003; 187: S346–S350.

8 Sharpe AH. Mechanisms of costimulation. Immunol Rev 2009; 229: 5–11.

9 Newton SMC, Wasley RD, Wilson A, Rosenberg LT, Miller JF, Stocker BA. Segment IV of a Salmonella flagellin gene specifies flagellar antigen epitopes. Mol Microbiol 1993; 5: 419–425.

10 Ciacci-Woolwine F, Blomfield IC, Richardson SH, Mizel SB. Salmonella flagellin induces tumor necrosis factor alpha in a human promonocytic cell line. Infect Immun 1998; 66: 1127–1134.

11 Wyant TL, Tanner MK, Sztein MB. Critical function for Naip5 in in vivo Salmonella infection. Infect Immun 1999; 67: 3619–3624.

12 McDermott PF, Ciacci-Woolwine F, Snipes JA, Mizel SB. High-affinity interaction between gram-negative flagellin and a cell surface polypeptide results in human monocyte activation. Infect Immun 2000; 68: 5525–5529.

13 Hayashi F, Means TK, Luster AD. Toll-like receptors stimulate human neutrophil function. Blood 2003; 102: 2660–2669.

14 Eaves-Pyles TD, Wong HR, Odoms K, Pyles RB. Salmonella flagellin-dependent proinflammatory responses are localized to the conserved amino and carboxyl regions of the protein. J Immunol 2001; 167: 7009–7016.

15 Murthy KKG, Deb A, Goenesisera S, Szabo C, Salzman AL. Identification of Conserved domains in Salmonella muenchen flagellin that are essential for its ability to activate TLR5 and to induce an inflammatory response in human epithelial cells. J Biol Chem 2004; 279: 56771–56779.

16 Ben-Yedidia T, Marcus H, Reisner Y, Amon R. Intranasal administration of peptide vaccine protects human/mouse radiation chimera from influenza infection. Int Immunol 1999; 11: 1043–1051.

17 Ben-Yedidia T, Aron R. Effect of pre-existing carrier immunity on the efficacy of synthetic influenza vaccine. Immunol Lett 1998; 64: 9–15.

18 Levi R, Amon R. Synthetic recombinant influenza vaccine induces efficient long-term immunity and cross-strain protection. Vaccine 1996; 14: 85–92.

19 Liu G, Tarbet B, Song L, Reiserova L, Weaver B, Chen Y et al. Immunogenicity and efficacy of flagellin-fused vaccine candidates targeting 2009 pandemic H1N1 influenza in mice. PLoS ONE 2011; 6: e20928.

20 Taylor DN, Treenor JJ, Strout C, Johnson C, Fitzgerald T, Kavita U et al. Induction of a potent immune response in the elderly using the TLR5 agonist, flagellin. Dev Comp Immunol 2014; 47: 90–94.

21 Tsujimoto H, Uchida T, Efron PA, Scumpia PO, Verma A, Matsumoto T. Flagellin enhances NK cell proliferation and activation directly and cytokine production. J Immunol 2009; 182: 1882–1885.

22 Lu J, Sun PD. The structure of the TLR5-flagellin complex: a new mode of pathogen detection, conserved receptor dimerization for signaling. Sci Signal 2012; 5: pl11.

23 Osvaldova A, Williams S, Patterson N, Offord Y, Mwangi D, Gibson AJ et al. Replacement of two aminoacids in the bovine Toll-like receptor 5 TIR domain with their human counterparts partially restores functional response to flagellin. Dev Comp Immunol 2014; 47: 90–94.

24 Kofoed EM, Vance RE. Innate immune recognition of bacterial ligands by cytoplasmic immunodulatory potential of flagellin. ImmunoRev 2012; 361–362.

25 Vicente-Suarez I, Brayer J, Villagra A, Cheng F, Sotomayor EM. TLR5 agonist, flagellin-sensing 3 binds figll-28 and activates the innate immune system. Nat Plants 2016; 2: 16128.

26 Godowski PJ, Madara JL. Cutting edge: flagellin enhances NK cell proliferation and activation directly and cytokine production. J Immunol 2009; 183: 8280–8285.

27 Haji IA, Dar PA, Chandrasekar S, Nanda RK, Kishore S, Bhanuprakash V et al. Flagellin effect on the serum regulatory factors: a novel finding. J Immunol 2008; 180: 7184–7192.

28 Bedoukian A, Zhang K, McNeil HP, Gioianno, D, Hampertozuian T, Wakefield D et al. Regulation of T lymphocyte trafficking into lymph nodes during an immune response by the chemokines macrophage inflammatory protein (MIP)-1 α and MIP-1 β. J Immunol 1998; 161: 5663–5672.

29 Vijayaraghavan R-M, Srinivasan A, Griffin A, Hauraz N, Eftet JM, Ravindran R et al. Salmonella flagellin induces bystander activation of splenic dendritic cells and hinders bacterial replication in vivo. J Immunol 2007; 179: 6169–6175.

30 Agrawal S, Agrawal A, Doughty B, Gerwitz A, Blenis J, Van Dyke T et al. Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos. J Immunol 2003; 171: 4984–4989.

31 Arimilli S, Johnson JB, Clark KM, Graff AH, Alexander-Miller MA, Mizel SB et al. Engineered expression of the TLR5 ligand flagellin enhances...
paramyxovirus activation of human dendritic cell function. J Virol 2008; 82: 10975–10985.
53 Umematsu S, Fujimoto K, Jiang MH, Yang B-G, Jung Y-J, Nishiyama M et al. Regulation of humoral and cellular gut immunity by lamina propria dendritic cells expressing Toll-like receptor 5. Nat Immunol 2008; 9: 769–776.
54 Datta SK, Redecke V, Prilliman KR, Takabayashi K, Corr M, Tallant T et al. A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells. J Immunol 2003; 170: 4102–4110.
55 Didierlaurent A, Ferrero I, Otten LA, Dubois B, Reinhardt M, Carlsen H et al. Flagellin promotes myeloid differentiation factor 88-dependent development of Th2-type response. J Immunol 2004; 172: 5922–5930.
56 Means TK, Hayashi F, Smith KD, Aderman A, Luster AD. The Toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells. J Immunol 2003; 170: 5165–5175.
57 Nossal G, Ada G, Austin CM. Antigens in immunity. Rev Vaccines 2008; 1587.
58 Yonekura K, Maki-Yonekura S, Namba K. Complete atomic model of the CAP53 helix-turn-helix domain. PLoS Biol 2005; 3:e256.
59 Sanders CJ, Yu Y, Moore DA, Williams IR, Gewirtz AT. Humoral immune response to Salmonella typhimurium Flagellin. Vaccine 2008; 26: 6132–6142.
60 Camacho AG, Teixeira LH, Bargieri DY, Boscardin SB, Soares I, da S et al. TL5-dependent immunogenicity of a recombinant fusion protein containing an immunodominant epitope of malarial circumsporozoite protein and the FIC flagellin of Salmonella Typhimurium. Mem Inst Oswaldo Cruz 2011; 106(Suppl 1): 167–171.
61 Eaves-Pyles T, Murthy K, Liuadet L, Virág L, Ross G, Soriano FG et al. Flagellin, a novel mediator of Salmonella-induced epithelial activation and systemic inflammation: I kappa B alpha degradation, induction of nitric oxide synthase, induction of proinflammatory mediators, and cardiovascular dysfunction. J Immunol 2001; 166: 1248–1260.
62 Berin MC, Darfeuille-Michaud A, Egan LJ, Miyamoto Y, Kagnoff MF. Role of HEC O157:H7 virulence factors in the activation of intestinal epithelial cell NF-kappaB and MAP kinase pathways and the upregulated expression of interleukin 8. Cell Microbiol 2002; 4: 635–648.
63 Steiner TS, Natano JP, Pootel-Smith CM, Smith JA, Guerant RL. Enterogegenerative Escherichia coli expresses a novel flagellin that causes IL-8 release from intestinal epithelial cells. J Clin Invest 2000; 105: 1769–1777.
64 Sierra F, Dubois B, Coste A, Kaiserlian D, Kraehenbuhl JP, Sirard JC. Flagellin stimulation of intestinal epithelial cells triggers CCL20-mediated induction of dendritic cells. Proc Natl Acad Sci USA 2001; 98: 13722–13727.
65 Zeng H, Carlson AQ, Guo Y, Yu Y, Collier-Hyams LS, Madara JL et al. Flagellin is the major proinflammatory determinant of enteropathogenic Salmonella. J Immunol 2003; 171: 3668–3674.
66 Ramos HC, Rumbo M, Sirard J-C. Bacterial flagellins: mediators of pathogenicity and host immune responses in mucosa. Trends Microbiol 2004; 12: 509–517.
67 Tezuka H, Abe Y, Iwata M, Takeuchi H, Ishikawa H, Matsuhashi M et al. Regulation of IgA production by naturally occurring TNF/INF-producing dendritic cells. Nature 2007; 448: 929–933.
68 Tezuka H, Abe Y, Asano J, Sato T, Liu J, Iwata M et al. Prominent role for plasminogen activator-induced dendritic cells in mucosal T cell-independent IgA induction. Immunology 2011; 11: 244–257.
69 Zhao X, Deak E, Soderberg K, Linehan M, Spezzano D, Zhu J et al. Vaginal submucosal dendritic cells, but not langerhans cells, induce protective Th1 responses to herpes simplex virus-2. J Exp Med 2003; 197: 153–162.
70 Ramamoorthy AJ, Husband AJ, Ramshaw IA, Bao S, Matthai KI, Koehler G et al. The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science 1994; 264: 561–563.
71 Lodes MJ, Cong Y, Elson CO, Mohamath R, Landers CJ, Targan SR et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest 2004; 113: 1296–1306.
72 Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005; 11: S45–S53.
73 Worbs T, Bode U, Yan S, Hoffmann MW, Hintzen G, Bernhardt G et al. Oral tolerance originates in the intestinal immune system and relies on antigen carriage by dendritic cells. J Exp Med 2006; 203: 519–527.
74 Girard A, Saran W, Bergeron-Sandoval L-P, Sarhan F, Archambault D. Flagellin produced in plants is a potent adjuvant for oral immunization. Vaccine 2011; 29: 6695–6703.
75 Hawin TR, Verbon A, Lettinga KD, Zhao LP, Li SS, Laws RJ et al. A common dominant TL5S stop codon polymorphism abolishes flagellin signaling and is associated with susceptibility to legionnaires’ disease. J Exp Med 2003; 198: 1563–1572.
76 Raeburn CD, Caikins CM, Zimmerman MA, Arya J, Barsness KA, Harken AH. Toll-like receptors and surgical disease. Surgery 2002; 131: 477–483.
77 Stockfleth E, Trefzer U, Garcia-Bartels C, Wegner T, Schmook T, Sterry W. The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview. Br J Dermatol 2009; 147: 53–56.
Experimental & Molecular Medicine

Okamoto M, Satoh M. Toll-like receptor signaling in anti-cancer immunity. J Med Invest 2003; 50: 9–24.

Kelly MG, Alvero AB, Chen R, Silasi D-A, Abrahams VM, Chan S et al. TLR-4 signaling promotes tumor growth and pachytxelx chemoresistance in ovarian cancer. Cancer Res 2006; 66: 3859–3868.

Szczenpanski MJ, Czywosz M, Szaunjik M, Harasymczuk M, Boyadzis M, Kruk-Zagajewska A et al. Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res 2009; 69: 3105–3113.

Chiron D, Pellat-Deceunynck C, Maillaissos M, Bataille R, Jego G. Phosphorothioate-modified TLR9 ligands protect cancer cells against TRAIL-induced apoptosis. J Immunol 2009; 183: 4371–4377.

Schmauder B, Andrilus M, Endrich S, Müller-Hermelink H-K, Eck M. Toll-like receptor ligands TRL4, TRL5 and TRL9 on gastric carcinoma cells: an implication for interaction with Helicobacter pylori. Int J Med Microbiol 2005; 295: 179–185.

Salaun B, Coste I, Rissoan M-C, Lebecke SJ, Renro T. TLR3 can directly trigger apoptosis in human cancer cells. J Immunol 2006; 176: 4894–4901.

Stondrni L, Rossini A, Besusso D, Merlo A, Tagliauoe E, Ménard S et al. Antitumor activity of the TLR-5 ligand flagellin in mouse models of cancer. J Immunol 2006; 176: 6624–6630.

Maerten P, Shen C, Bullens DMA, Van Assche G, Van Gool S, Geoboos K et al. Effects of interleukin 4 on CD25+CD4+ regulatory T cell function. J Autoimmun 2005; 25: 112–120.

Napolitano G, Rinaioli A, Bertoni F, Sallusto F, Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1–polarizing program in dendritic cells. Nat Immunol 2005; 6: 769–776.

Zheng JH, Nguyen VH, Jiang S, Park S, Tan W, Hong SH et al. Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin. Science Transl Med 2017; 9537: 1–11.

Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007; 13: 552–559.

Tukhvatulin AI, Gitlin II, Shcheblyakov DV, Artemicheva NM, Burdelya LG, Krivokrysenko VI, Tallant TC, Strom E, Gleiberman AS, Berger AL, High CD, Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Endotoxin-induced lung injury in mice: structural, functional, and biochemical responses. AJP Lung Cell Mol Physiol 2008; 288: L333–L341.

Wani MY, Goswami TK, Chaudhary D, Singh R, Dhama K. Mitigation of septic signs by pravastatin during LPS co-administered hen-egg white lysozyme immunization in mice. Int J Pharmacol 2014; 10: 389–397.

Gewirtz AT. Intestinal epithelial toll-like receptors: to protect. And serve? Nat Immunol 2006; 7: 3855–3864.

Lee SE, Koh YJ, Kim M-K, Kim YR, Kim SY, Nam JH et al. Inhibition of airway allergic disease by co-administration of flagellin with allergen. J Clin Immunol 2008; 28: 157–165.

Rhee SH, Im E, Pothoulakis C. Toll-like receptor 5 engagement modulates immune reactions and resistance to Salmonella enterica serovar typhimurium infection. Infect Immun 2013; 81: 3855–3864.

Yan X, Guo C, Yi H, Qian J, Fisher PB, Subjeck JR et al. A multifunctional chimeric chaperone serves as a novel immune modulator inducing therapeutic antitumor immunity. Cancer Res 2013; 73: 2093–2103.

Kaczanowska S, Davila E. Ameliorating the tumor microenvironment for cancer development and protecting the tumor from immune attack. Cancer Res 2009; 69: 3105–3113.

Berdelya LG, Krivokrysenko VI, Tallant TC, Lee SE, Koh YI, Kim M-K, Nam JH. Evaluation of a truncated recombinant flagellin vaccine in mice. Proc Natl Acad Sci USA 2016; 113: E874–E883.

Ben-Yedidia T, Abel L, Arnon R, Globerson A. Efficient generation of therapeutic antitumor immunity using synthetic recombinant peptide-based vaccine protects aged mice from infection by Schistosoma mansoni. Infection Immun 2014; 82: 3520–3529.

Song L, Nakao V, Kavita U, Price A, Huleatt J, Tang J et al. Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs. PLoS ONE 2008; 3: e2257.

Song L, Zhang Y, Yun NE, Poussard AL, Smith JN, Smith JK et al. Superior efficacy of recombinant flagellin: H5N1 HA globular head vaccine is determined by the placement of the globular head within flagellin. Vaccine 2009; 27: 5875–5884.

Lee S, Song L, Reiserova L, Trivedi U, Li H, Liu X et al. Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections. Vaccine 2012; 30: 6833–6838.

Wang B-Z, Quan F-S, Kang S-M, Bozja J, Skountzou I, Compans RW et al. Evaluation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J Virol 2008; 82: 11813–11823.

McSorley SJ, Esh HD, Yu Y, Gewirtz AT. Bacterial flagellin is an effective adjuvant for CD4+ T cells in vivo. J Immunol 2002; 169: 3914–3919.

McSorley SJ, Cookson BT, Jenkins MK. Characterization of CD4+ T cell responses during natural infection with Salmonella typhimurium. J Immunol 2000; 164: 986–993.

Ben-Yedidia T, Abel L, Arnon R, Gliberson A. Efficacy of anti-influenza peptide vaccine in aged mice. Mech Ageing Dev 1998; 104: 11–23.

Bates JT, Honko AN, Graff AH, Kock ND, Mizel SB. Mucosal adjuvant activity of anti-influenza peptide-based vaccines squares enhanced T cell responses. J Biol Chem 2005; 280: 20620–20627.

Nguyen CT, Hong SH, Sin JI, Yu HVD, Jeong K, Cho KO et al. Flagellin enhances tumor-specific CD8+ T cell immune responses through TLR5 stimulation in a therapeutic cancer vaccine model. Vaccine 2013; 31: 3879–3887.
141 Weimer ET, Lu H, Kock ND, Wazniak DJ, Mizel SB. A fusion protein vaccine containing Opf epitope B, Opf1, and type A and B flagellins promotes enhanced clearance of nonmucoid Pseudomonas aeruginosa. Infect Immun 2009; 77: 2356–2366.

142 Asadi Karam MR, Oloomi M, Mahdavi M, Habibi M, Bouzari S. Vaccination with recombinant FimH fused with flagellin enhances cellular and humoral immunity against urinary tract infection in mice. Vaccine 2013; 31: 1210–1216.

143 Rady HF, Dai G, Huang W, Shellito JE, Ramsay AJ, Li Y. Flagellin encoded in gene-based vector vaccines is a route-dependent immune adjuvant. PLoS ONE 2016; 11: e0148701.

144 Hiriart Y, Rossi AH, Biedma ME, Errea AJ, Moreno G, Cayet D et al. Characterization of structural and immunological properties of a fusion protein between flagellin from Salmonella and lumazine synthase from Brucella. Protein Sci 2017; 26: 1049–1059.

145 Delaney KN, Phipps JP, Johnson JB, Mizel SB. A recombinant flagellin-poxvirus fusion protein vaccine elicits complement-dependent protection against respiratory challenge with vaccinia virus in mice. Viral Immunol 2010; 23: 201–210.

146 Vassilieva EV, Wang B, Vzorov AN. Enhanced mucosal immune responses to HIV virus-like particles containing a membrane-anchored adjuvant. MBio 2011; 15: e00328–10.

147 Qi Y, Kang H, Zheng X, Wang H, Gao Y, Yang S et al. Incorporation of membrane-anchored flagellin or Escherichia coli heat-labile enterotoxin B subunit enhances the immunogenicity of rabies virus-like particles in mice and dogs. Front Microbiol 2015; 6: 169.

148 Bargieri DY, Rosa DS, Braga CJM, Carvalho BO, Costa FTM, Espindola NM et al. New malaria vaccine candidates based on the Plasmodium vivax merozoite surface protein-1 and the TLR-5 agonist Salmonella typhimurium FltC flagellin. Vaccine 2008; 26: 6132–6142.

149 Braga CJM, Massis LM, Sbrogio-Almeida ME, Alencar BCG, Bargieri DY, Boscardin SB et al. CD8+ T cell adjuvant effects of Salmonella FltC flagellin in live vaccine vectors or as purified protein. Vaccine 2010; 28: 1373–1382.

150 Yin G, Qin M, Liu X, Suo J, Tang X, Tao G et al. An Eimeria vaccine candidate based on Eimeria tenella immune mapped protein 1 and the TLR-5 agonist Salmonella typhimurium FltC flagellin. Biochim Biophys Acta 2013; 440: 437–442.

151 Cuadros C, Lopez-hernandez FJ, Dominguez AL, Mcclelland M, Lustgarten J. Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses. Infect Immun 2004; 72: 2810–2816.

152 Huleatt JW, Jacobs AR, Tang J, Desai P, Kopp EB, Huang Y et al. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 2007; 25: 763–775.

153 Nyström S, Bååke A, Falkeborn T, Devito C, Rissiek B, Johannson D et al. DNA-encoded flagellin activates Toll-like receptor 5 (TLR5), nod-like receptor family CARD domain-containing protein 4 (NRLC4), and acts as an epidermal, systemic, and mucosal-adjuvant. Vaccines 2013; 1: 415–443.

154 Lockner JW, Eubanks LM, Choi JL, Lively JM, Schlosburg JE, Collins KC et al. Flagellin as carrier and adjuvant in cocaine vaccine development. Mol Pharm 2015; 12: 653–662.

155 Cai Z, Sanchez A, Shi Z, Zhang T, Liu M, Zhang D. Activation of Toll-like Receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth. Cancer Res 2011; 71: 2466–2475.

156 Shi M, Yao Y, Han F, Li Y, Li Y, Takeuchi O et al. MAP1S controls breast cancer cell TLR5 signaling pathway and promotes TLR5 signaling-based tumor suppression. PLoS ONE 2014; 9: e86839.

157 Izidoro MS Jr, Varela JN, Alves DA, Pereira RFC, Brocchi M, Lancellotti M et al. Effects of Salmonella enteritidis serovar typhimurium infection in adenocarcinomic human alveolar basal epithelial cells A549 in vitro: bacteria induce apoptosis in adenocarcinomic cell. J Bacterial Parasitol 2012; 3: 158.

158 Machliuf N, Arnon R. Therapeutic MUC1-based cancer vaccine expressed in flagella-efﬁcacy in an aggressive model of breast cancer. World J Vaccines 2012; 2: 109–120.

159 de Melo FM, Braga CJ, Pereira FV, Maricato JT, Origassa CS, Souza MF et al. Anti-metastatic immunotherapy based on mucosal administration of flagellin and immunomodulatory P10. Immunol Cell Biol 2015; 93: 86–98.